Micrima Limited

A lovely meal, with a fantastic group of people as we kick off something truly amazing. Over the past two years we have taken wholly novel technology, developed over the best part of 20 years and transformed it into something that just isn’t available with any other technology. The hurdles involved with getting novel MedTech to market are more significant than I ever imagined, when I joined this business three years ago. But, we have never lost sight of what we are trying to achieve and the difference this technology can make to the 10% of women who will die as a result of late diagnosis. I’ve never felt more confident that we are on the verge of something truly game changing. I send a heartfelt thanks to everyone who has supported us. From our dedicated and incredibly talented staff, committed and compassionate clinical partners and our investors, who without their trust and belief we simply wouldn’t be here. Breast cancer we are coming for you! #finditearly #breastcancer #breastdensity Micrima Limited

Around 40% of women have a breast density measurement of BI-RADS b. Women in this category have breasts with a lot of fatty tissue and scattered areas of fibroglandular tissue. Women with breasts in this category are classified as having low breast density. On a screening mammogram (pictured), fat appears dark and glandular tissue appears white, so a mammogram of breasts with low breast density can more easily show abnormal findings, including breast cancer which typically shows up as white. A breast density category of BI-RADS b is more common in older women, as breasts become less dense with age. If you have a breast density measurement of BI-RADS b - it is still important that you have your regular breast screen (every 2 years) and be breast aware between screening appointments. All women who screen at #BreastScreenSA receive information about their breast density in their results letter. Find out more about breast density on our website: https://lnkd.in/gesQePnN

NEWS: Two More U.S. State Insurance Laws Two new states, Iowa and Vermont, have enacted insurance laws for expanded breast imaging coverage after a mammogram! Now 29 states have enacted laws for some level of additional insurance coverage after a mammogram. Details here: https://lnkd.in/e3jtu9g

We're hiring talent! Are you coming out of education and looking for an incredible opportunity, to get involved with supporting the early stage launch of our ground breaking breast cancer detection technology? Working from our incredible location in Glass Wharf, Bristol, you'll need an eye for detail as you complete market research, assist with grant applications, support development of new clinical trials and provide general support to the team. In return you'll report straight in to the most senior members of the team with fantastic opportunities to learn, grow and make a difference as you grow with us. Interested in finding out more? Please email [email protected] for more details.

Great news for women in the US as their preventative service task force recommends lowering the age of breast screening commencement to 40. It is another step forward for all those who have been working so hard to deliver screening to a wider pool of women but to also ensure they have the right test for their breast tissue type. Lowering of the recommended screening age as well as implementing mandatory breast density information pushes the US beyond where we are in Europe, albeit not as far as we had all hoped in mandating supplemental testing for women with dense breast tissue. Dense fibroglandular tissue has a significant impact on the ability for a standard mammogram to detect cancer in “dense” breasts (as low as 4 in 10 in some cases). This is a problem that affects around 50% of the existing screening population. Density decreases with age so lowering the screening age will only increase the number of women impacted by density. Suppliers of Mammography equipment have been working for decades to improve these detection rates and there is much clinical evidence that indicates a significant improvement in detection rates by applying different Mammography techniques (like Tomosynthensis (3D) or the use of a pre Mammogram injection of Iodine, as a contrast agent). These techniques can deliver detection rates that deliver similar detection rates for all women and all breast tissue types. The issue is you have to know breast density up front to understand the most appropriate diagnostic technique, or else the only option is to lead with a standard Mammogram that isn’t the best test (to detect cancer) for over 50% of women and then follow with a second test for those with dense breasts. At Micrima Limited we have developed a handheld and portable scanner that uses radiowave technology, developed over a twenty year period, to measure breast density ahead of any imaging. It’s super quick, safe, pain free and can be operated by anyone after just 30 minutes of training. Its use can transform pathways by enabling selection of the best imaging technique, to detect cancer, in each individual patients breast tissue type first time. This takes away the issues of cost and capacity of 2 tests for the 50% of women who have a standard mammogram and then require supplemental tests, when they are found to have dense breast tissue. Over 1 in 8 women will get breast cancer in their lifetime. That’s 500M women alive today that will experience breast cancer at some point post puberty. Survival rates are incredible, if that cancer is detected whilst still localised in the breast (around 99%) but drop significantly if that cancer is only found once it has spread outside of the breast. Ultimately 1 in 10 of women, who get breast cancer will die purely as a result of late detection. That’s 50 MILLION women alive today. So let’s all keep working together to both develop new technology and spread awareness amongst women and change these statistics.